FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents.
Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, idelalisib, veltuzumab, XmAb5574, navitoclax, dasatinib, alvespimycin, and TRU-016. This review summarizes the most current clinical experiences with these agents in the treatment of CLL.
31 December 2025 in Cellular Physiology and Biochemistry
Background/Aims: Acute myeloid leukemia (AML) is a devastating hematological malignancy without a definitive cure. 6-Gingerol, a bioactive compound, has shown promise in treating various cancers, yet its impact on AML remains elusive. Methods: To elucidate the potential of 6-gingerol in AML, we conducted comprehensive experiments. Cell growth and clonogenic capacity were assessed using CCK-8 testing and colony formation assays. Flow cytometry was employed to analyze cell cycle progression and apoptosis. The invasive capability of AML cells was evaluated through the Transwell migration assay. Fluorescent probe staining was used to determine intracellular reactive oxygen species (ROS) concentration, while Western Blot was utilized to assess the expression levels of key proteins including Bcl-2, caspase3, MAPK, and p-MAPK in AML cells. Potential targets of 6-gingerol in AML were identified through various bioinformatics databases such as STP, SEA, STICH, OMIM GeneMap, and GeneCards. Enrichment analysis of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways was performed using the cluster Profiler package (v4.16.0). Results: Our findings indicated that 6-gingerol effectively inhibits proliferation, colony formation, and invasive capacity of AML cells, arresting them at the G1 phase of the cell cycle. Furthermore, 6-gingerol enhanced the expression levels of ROS, caspase 3, MAPK, and p-MAPK in AML cells. 67 overlapping targets between 6-gingerol and AML were identified, which are enriched within the MAPK signaling pathway and ROS-related pathways. Notably, NFKB1 emerged as a pivotal hub gene through which 6-gingerol exerts its influence on AML. Conclusion: 6-Gingerol could act as a promising agent sourced from Traditional Chinese Medicine (TCM) for AML treatment.